Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00417963 | ViVEXX Carotid Revascularization Trial (VIVA) | PHASE3 | COMPLETED | 407 | — | — | Oct 1, 2005 | Mar 1, 2010 | Mar 1, 2017 | - | — |
A composite of major adverse events (MAE) including any death, any stroke and/or myocardial infarction occurring during the first 30 days post-procedure and ipsilateral stroke between 31 and 365 days post procedure.
| Arm | Type | Description |
|---|---|---|
| stent placement in the carotid artery | EXPERIMENTAL | placement of a bare metal stent for treatment of carotid artery stenosis |
| Name | Type | Description |
|---|---|---|
| Carotid Artery Stenting | DEVICE | placement of a bare metal stent at sites of stenosis in the carotid artery |
Inclusion Criteria: * The patient has a symptomatic or asymptomatic carotid artery stenosis that meets one of the following criteria: * Symptomatic: \> than or = to 50% carotid stenosis by angiography and a history of non-disabling stroke, transient ischemic attack (TIA) in the hemisphere suppli...